Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093701 · ClinicalTrials.gov registry record · Phase 2
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
A Phase 2 study, sponsored by Taiwan Liposome Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03093701: Completed Phase 2 study, sponsored by Taiwan Liposome Company.
NCT03093701 is a Phase 2 study that has completed, run by Taiwan Liposome Company. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03093701, a Phase 2 study, has completed, sponsored by Taiwan Liposome Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
Primary Outcome
Proportion of subjects with BCVA gain of 15 or more letters from baseline in the study eye. Patients who received rescue medication/procedures within 6 months after the study treatment was initiated were considered failure to achieve a gain of at least 15 BCVA letters.
Interventions
- DRUG TLC399 (ProDex)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 2 |
What the finished NCT03093701 record still lists
NCT03093701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which TLC399 (ProDex) is the first listed.
NCT03093701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03093701 about?
NCT03093701 is a clinical study titled "TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)". Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
What is the current status of trial NCT03093701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2017-04-01. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03093701?
The interventions under investigation include: TLC399 (ProDex) (DRUG).
Who is sponsoring clinical trial NCT03093701?
This trial is sponsored by Taiwan Liposome Company, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03093701's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI